Technical Analysis for LABP - Landos Biopharma, Inc.

Grade Last Price % Change Price Change
A 6.64 0.00% 0.00
LABP closed unchanged on Monday, March 18, 2024, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Mar 21
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Reached Overbought Strength 2.47%
Inside Day Range Contraction 2.47%
Overbought Stochastic Strength 2.47%
Gapped Down Weakness 2.47%
Gapped Down Weakness 2.47%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 19 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Fell Below 20 DMA about 19 hours ago
Fell Below 10 DMA about 19 hours ago
10 DMA Support about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy

Is LABP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.73
52 Week Low 2.328
Average Volume 10,942
200-Day Moving Average 4.29
50-Day Moving Average 5.48
20-Day Moving Average 6.34
10-Day Moving Average 6.49
Average True Range 0.41
RSI (14) 68.85
ADX 15.62
+DI 15.36
-DI 13.99
Chandelier Exit (Long, 3 ATRs) 5.50
Chandelier Exit (Short, 3 ATRs) 6.48
Upper Bollinger Bands 6.88
Lower Bollinger Band 5.80
Percent B (%b) 0.78
BandWidth 17.06
MACD Line 0.32
MACD Signal Line 0.35
MACD Histogram -0.0292
Fundamentals Value
Market Cap 20.7 Million
Num Shares 3.12 Million
EPS -3.85
Price-to-Earnings (P/E) Ratio -1.72
Price-to-Sales 2.37
Price-to-Book 0.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.20
Resistance 3 (R3) 7.15 6.91 7.10
Resistance 2 (R2) 6.91 6.77 6.94 7.07
Resistance 1 (R1) 6.78 6.68 6.66 6.83 7.04
Pivot Point 6.54 6.54 6.49 6.57 6.54
Support 1 (S1) 6.41 6.40 6.29 6.46 6.24
Support 2 (S2) 6.17 6.31 6.20 6.21
Support 3 (S3) 6.04 6.17 6.18
Support 4 (S4) 6.09